Department of Gastroenterological Surgery, Osaka General Medical Center, Osaka, Japan.
Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan.
Eur J Cancer. 2024 Dec;213:115080. doi: 10.1016/j.ejca.2024.115080. Epub 2024 Oct 20.
Potential benefit of surgical resection for liver metastasis from gastric cancer (LMGC) remains controversial because most previous studies were retrospective. We evaluated the outcomes of surgical resection following chemotherapy for LMGC in a prospective single-arm multicenter interventional study.
Patients with synchronous or metachronous LMGC received 2-4 cycles of standard chemotherapy and proceeded to surgical resection if restaging showed a non-progressive disease with a chance of R0 resection. The primary endpoint was 3-year OS of R0 patients, with RFS as secondary. Prognostic factors for R0 patients were evaluated by multivariable Cox regression analysis.
Seventy patients were enrolled between 2011 and 2019. Two patients were ineligible, and 20 discontinued treatment before surgery. Of the 48 patients eventually undergoing surgery, 43 accomplished R0 resection of the primary and/or metastatic GC, while 1 ended in R2 resection and 4 were considered ineligible. Median and 3-year OS for R0 patients were 39.8 months (95 % confidence interval [CI], 26.9 to not reached) and 58.1 % (95 % CI, 43.1-71.8), respectively, while median and 3-year RFS were 14.9 months (95 % CI 7.9-34.0) and 34.9 % (95 % CI 22.2-50.1), respectively. On multivariable analysis, both multiple liver metastases and positive nodal status (pN1-3) were negatively associated with OS (multiple liver metastases: hazard ratio [HR] 2.71 (95 % CI, 1.16-6.35), P = 0.022; pN1-3: HR 9.11 (95 % CI, 1.22-68.2), P = 0.031).
R0 resection following chemotherapy for LMGC yielded promising survival, with multiple liver metastases and positive nodal status being significant indicators of poor prognosis.
UMIN 000011445 (https://www.umin.ac.jp/ctr/).
胃转移癌肝转移(LMGC)的手术切除的潜在益处仍存在争议,因为大多数先前的研究都是回顾性的。我们在一项前瞻性单臂多中心干预研究中评估了化疗后手术切除 LMGC 的结果。
患有同步或异时性 LMGC 的患者接受 2-4 个周期的标准化疗,如果重新分期显示非进展性疾病并有机会进行 R0 切除,则进行手术切除。主要终点是 R0 患者的 3 年 OS,次要终点是 RFS。通过多变量 Cox 回归分析评估 R0 患者的预后因素。
2011 年至 2019 年间共纳入 70 例患者。2 例患者不符合条件,20 例患者在手术前停止治疗。最终接受手术的 48 例患者中,43 例患者成功进行了原发性和/或转移性 GC 的 R0 切除,1 例患者 R2 切除,4 例患者被认为不符合条件。R0 患者的中位和 3 年 OS 分别为 39.8 个月(95%CI,26.9 至未达到)和 58.1%(95%CI,43.1-71.8),中位和 3 年 RFS 分别为 14.9 个月(95%CI,7.9-34.0)和 34.9%(95%CI,22.2-50.1)。多变量分析显示,多发肝转移和阳性淋巴结状态(pN1-3)与 OS 呈负相关(多发肝转移:HR 2.71(95%CI,1.16-6.35),P=0.022;pN1-3:HR 9.11(95%CI,1.22-68.2),P=0.031)。
LMGC 化疗后行 R0 切除术可获得较好的生存,多发肝转移和阳性淋巴结状态是预后不良的显著指标。
UMIN 000011445(https://www.umin.ac.jp/ctr/)。